Denver, CONCT06566079Now EnrollingIRB Ready

Malignant Mesothelioma Clinical Trial in Denver, CO

Access cutting-edge malignant mesothelioma treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by InSilico Medicine Hong Kong Limited

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access malignant mesothelioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant mesothelioma treatment provided free

Apply for This Denver Location

Check if you qualify for this malignant mesothelioma clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Malignant Mesothelioma Study in Denver

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).

Sponsor: InSilico Medicine Hong Kong Limited

Who Can Participate

Inclusion Criteria

Male or female participants with age ≥18 years at the time of signing the informed consent.
Histologically confirmed unresectable advanced or metastatic malignant mesothelioma or other solid tumors, who have failed standard therapy or for whom no effective standard therapy exists, participants for part 1 is regardless of the presence or absence of the genetic alterations of the Hippo pathway, but for part 2 participants with solid tumors other than mesothelioma, genetic testing documentation must demonstrate Hippo signaling pathway dysregulation.
Participants with malignant mesothelioma must have prior exposure to at least immune checkpoint therapy and platinum-based chemotherapy.
Presence of at least one evaluable lesion in Part 1 or one measurable target lesion in Part 2 according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for participants with non-pleural mesothelioma or other solid tumors and modified RECIST (mRECIST) v1.1 for participants with malignant pleural mesothelioma.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.
Life expectancy of ≥12 weeks as judged by the investigator.
Adequate organ function as determined by medical assessment (within 7 days prior to the first dose of study treatment).
Capable of providing signed informed consent form (ICF) and complying with the requirements and restrictions listed in the ICF and in this study protocol.

Exclusion Criteria

Participants who have previously received a TEAD inhibitor.
Participation in other therapeutic clinical studies within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment.
Anti-tumor therapy within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment.
Known active central nervous system (CNS) primary tumor or untreated CNS metastases.
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases.
Unwillingness or unable to comply with the requirements of oral drug administration, or presence of a gastro-intestinal condition
Have prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, laboratory abnormality or any other conditions that, in the investigator's opinion, would not be in the best interest of the participant; or that could alter the absorption, distribution, metabolism, or excretion of the study treatment; or impair the assessment of study result.
Currently receiving any of Strong inhibitors or inducers of P-gp, or Sensitive substrates of P-gp, CYP1A2, CYP2B6, and CYP3A4 that cannot be discontinued 14 days or 5 half-lives for inhibitors or substrates (whichever is shorter) prior to the first dose of study treatment. Other protocol inclusion and exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT06566079) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Mesothelioma Treatment Options in Denver, CO

If you're searching for malignant mesothelioma treatment options in Denver, CO, this clinical trial (NCT06566079) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced malignant mesothelioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant mesothelioma clinical trials near you to find additional studies recruiting in your area.

More Mesothelioma Trials in Denver, CO

See all mesothelioma clinical trials recruiting in Denver — not just this study.

Browse Mesothelioma Trials in Denver →

Browse More Trials by Condition

Mesothelioma TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO